98%
921
2 minutes
20
Office-based activity reduces sedentariness, yet no randomized controlled trials (RCTs) have assessed how such activity influences visceral adipose tissue (VAT). This study examined the effect of an office-based, multicomponent activity intervention on VAT. The WorkACTIVE-P RCT enrolled sedentary office workers (body mass index: 31.4 (standard deviation (SD) 4.4) kg/m) to an intervention ( = 20) or control ( = 20) group. For 3 months, the intervention group received an office-based pedal desk, further to an intervention promoting its use and increased walking. The control group maintained habitual activity. At baseline and follow-up, VAT, cardiometabolic disease risk markers, physical activity, and food intake were measured. Steps/day were not altered relative to control ( ≥ 0.51), but the pedal desk was utilized for 127 (SD 61) min/day. The intervention reduced VAT relative to control (-0.15 kg; 95% confidence interval (CI) = -0.29 to -0.01; = 0.04). Moreover, the intervention decreased fasting glucose compared with control (-0.29 mmol/L; 95% CI = -0.51 to -0.06; = 0.01), but no differences in other cardiometabolic disease markers or food intake were revealed ( ≥ 0.11). A multicomponent intervention decreased VAT in office workers who were overweight or obese. Though longer-term studies are needed, office-based, multicomponent activity regimens may lower cardiometabolic disease risk. Trial registered at ClinicalTrials.gov (NCT02561611). In WorkACTIVE-P, a multicomponent activity intervention decreased visceral adipose tissue relative to control in office workers. The intervention also reduced glucose compared with control, though other metabolic risk markers and food intake were not altered. Such multicomponent interventions could help reduce cardiometabolic disease risk, but longer studies are needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872101 | PMC |
http://dx.doi.org/10.1139/apnm-2020-0175 | DOI Listing |
Diabetes Obes Metab
September 2025
Epidemiology, IQVIA, Frankfurt, Germany.
Aims: To examine the association between elevated body mass index (BMI) and a wide range of vascular and cardiometabolic diseases in men and women.
Materials And Methods: This retrospective cohort study used data from the IQVIA Disease Analyzer database, comprising anonymized records from over 3000 office-based physicians in Germany. We included 233 730 patients aged ≥40 years with at least one recorded BMI measurement between January 2005 and December 2023.
Int J Cardiol Heart Vasc
October 2025
Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.
Front Psychiatry
August 2025
Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia.
Background: Cardiovascular diseases (CVDs) are a leading cause of death worldwide. Healthcare workers are at increased risk due to workplace stressors such as long hours, shift work, and high job demands, which may worsen both modifiable and non-modifiable CVD risk factors. This systematic review examines the impact of these workplace stressors on the risk for CVD among healthcare providers.
View Article and Find Full Text PDFBackground: Previous studies have demonstrated that both obesity and metabolic heterogeneity impact cardiovascular disease. However, the effect of different body mass index (BMI)-metabolic phenotypes on the progression of cardiometabolic multimorbidity (CMM) remains unclear.
Methods: This study utilized baseline data from the China Health and Retirement Longitudinal Study (CHARLS) in 2011, enrolling 5,850 participants for a longitudinal cohort analysis.
Curr Opin Lipidol
August 2025
Cardiometabolic Immunity Laboratory, Department of Physiology, Monash Biomedicine Discovery Institute (BDI) and Victorian Heart Institute (VHI), Monash University, Melbourne, Victoria, Australia.
Purpose Of Review: This review explores the evolving understanding of efferocytosis - the clearance of dead or dying cells by phagocytes - in the context of atherosclerosis. It highlights recent discovers in cell death modalities, impaired clearance mechanisms and emerging therapeutic strategies aimed at restoring efferocytosis to stabilize plaques and resolve inflammation.
Recent Findings: Recent studies have expanded the scope of efferocytosis beyond apoptotic cells to include other pro-inflammatory cell death modes, including pyroptosis, necroptosis and ferroptosis, revealing context-dependent clearance efficiency and immunological outcomes.